

FISCAL IMPACT OF PROPOSED LEGISLATION

79th Oregon Legislative Assembly – 2017 Regular Session
Legislative Fiscal Office

Measure: SB 793 - 2

***Only Impacts on Original or Engrossed
Versions are Considered Official***

Prepared by: Meg Bushman-Reinhold
Reviewed by: Steve Bender, Linda Ames, John Borden, Matt Stayner, Kim To
Date: 4/13/2017

Measure Description:

Requires prescription drug manufacturer to report to Department of Consumer and Business Services prices and increases in prices of manufacturer's prescription drugs sold in Oregon.

Government Unit(s) Affected:

Board of Pharmacy, Department of Consumer and Business Services (DCBS), Department of Justice, Judicial Department, Oregon Health Authority (OHA)

Analysis:

This fiscal impact statement is for the purpose of transmitting the measure from the Senate Committee on Health Care to the Joint Committee on Ways and Means. The bill requires prescription drug manufacturer to report to Department of Consumer and Business Services prices and increases in prices of manufacturer's prescription drugs sold in Oregon. A more complete fiscal analysis on the bill will be prepared as the measure is considered in the Joint Committee on Ways and Means.

Further Analysis Required